TRINETRA › Sectors › Healthcare
Suven Life Sciences Limited (SUVEN) — share price, P/E and fundamentals
Suven Life Sciences Limited (NSE: SUVEN) closed at ₹259.50 on 30 Oct 2026, +35.5% over one year, against a 52-week range of ₹124.11 – ₹403.35.
In the quarter ended 30 Jun 2026 (consolidated, filed 6 Aug 2026) it reported revenue of ₹4 cr and a net loss of ₹128 cr; revenue grew 91.0% year on year.
No trailing P/E is published: trailing twelve-month earnings are negative (-352 cr), so a P/E has no meaning — a loss-making business is not 'cheap' at a negative multiple. Judge it on revenue growth, cash burn and funding instead.
From the balance sheet dated 31 Mar 2026: return on equity -86.3%, ROCE -85.7%, debt-to-equity 0.00, Piotroski F-score 4 of 9.
Against 65 Healthcare peers on NSE: ROE higher than 0% of 63 sector peers; ROCE higher than 0% of 63 sector peers; Debt / equity lower than 88% of 64 sector peers.
Key figures
| Last close | ₹259.50 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -22.5% / +28.4% / +35.5% |
| 52-week low – high | ₹124.11 – ₹403.35 |
| Market capitalisation | ₹6,851 cr |
| Price / book | 11.58 |
| TTM EPS | ₹-13.35 |
| TTM net profit | ₹-352 cr |
| Quarter revenue | ₹4 cr |
| Quarter net loss | ₹128 cr |
| Revenue growth (YoY) | +91.0% |
| Profit growth (YoY) | -147.7% |
| Return on equity | -86.3% |
| ROCE | -85.7% |
| Debt / equity | 0.00 |
| Current ratio | 17.69 |
| Free cash flow | ₹-307 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹17.1 cr |
Against Healthcare peers
| Metric | SUVEN | Peer median | Percentile |
|---|---|---|---|
| ROE | -86.31 | 13.87 | 0 |
| ROCE | -85.71 | 17.26 | 0 |
| Debt / equity | 0.00 | 0.11 | 12 |
| P/B | 11.58 | 5.88 | 77 |
Questions
What were Suven Life Sciences Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Suven Life Sciences Limited reported revenue of ₹4 cr and a net loss of ₹128 cr (consolidated), filed with the exchange on 6 Aug 2026.
What is Suven Life Sciences Limited's ROE?
Return on equity is -86.3% based on the balance sheet dated 31 Mar 2026.
Does Suven Life Sciences Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.
What is SUVEN's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SUVEN traded between ₹124.11 and ₹403.35.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.